There were three patients with EGFR-mutated tumors (arm A: EGFR insertion exon 20; arm B: EGFR deletion exon 19 and co-mutation of EGFR p.G719A and p.S768I), who had 95% (arm A) and 50% viable tumor cells (both in arm B) following study therapy. Here, EGFR is linked to neoplasm.